Individual HIV type 1 envelope-specific T cell responses and epitopes do not segregate by virus subtype

AIDS Research and Human Retroviruses

Volumn 22, Issue 2, 2006, Pages 188-194

  Brown, S A ^a   Slobod, K S ^a,b   Surman, S ^a   Zirkel, A ^a   Zhan, X ^a   Hurwitz, Julia L ^a,b,c  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c Department of Infectious Diseases ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS ENVELOPE PROTEIN;

ARTICLE; CROSS REACTION; DNA FLANKING REGION; HUMAN IMMUNODEFICIENCY VIRUS 1; HYBRIDOMA; IMMUNE RESPONSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; T LYMPHOCYTE;

AMINO ACID SEQUENCE; EPITOPES; GENES, ENV; HIV-1; HUMANS; MOLECULAR SEQUENCE DATA; T-LYMPHOCYTES;

EID: 33244482028     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2006.22.188     Document Type: Article

References (15)

1. Gaschen B, Taylor J, Yusim K, et al.: Diversity considerations in HIV-1 vaccine selection. Science 2002;296(5577):2354-2360.
2. Martin JE, Enama ME, Koup RA, et al.: VRC 004: Safety and immunogenicity of a multiclade HIV-1 DNA vaccine in healthy uninfected adults (VRC-HIVDNA009-00-VP). J Allergy Clin Immunol 2005;115(4):892.
3. Binley JM, Wrin T, Korber B, et al.: Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol 2004;78(23):13232-13252.
4. Weber J, Fenyo EM, Beddows S, Kaleebu P, and Bjorndal A: Neutralization serotypes of human immunodeficiency virus type 1 field isolates are not predicted by genetic subtype. The WHO Network for HIV Isolation and Characterization. J Virol 1996;70(11): 7827-7832.
5. Surman S, Lockey TD, Slobod KS, et al.: Localization of CD4+ T cell epitope hotspots to exposed strands of HIV envelope glycoprotein suggests structural influences on antigen processing. Proc Natl Acad Sci USA 2001;98:4587-4592.
6. Lockey TD, Surman S, Brown S, et al.: A five-residue HIV envelope helper T cell determinant: Does this peptide-MHC interaction leave the binding groove half empty? AIDS Res Hum Retroviruses 2002;18(15):1141-1144.
7. Zhan X, Slobod KS, Surman S, et al.: Limited breadth of a T-helper cell response to a human immunodeficiency virus envelope protein. J Virol 2003;77(7):4231-4236.
8. McElrath MJ, Siliciano RF, and Weinhold KJ: HIV type 1 vaccine-induced cytotoxic T cell responses in phase I clinical trials: Detection, characterization and quantitation. AIDS Res Hum Retroviruses 1997;13(3):211-216.
9. Seaman MS, Xu L, Beaudry K, et al.: Multiclade human immunodeficiency virus type 1 envelope immunogens elicit broad cellular and humoral immunity in rhesus monkeys. J Virol 2005;79(5):2956-2963.
10. Chakrabarti BK, Ling X, Yang Z-Y, et al.: Expanded breadth of virus neutralization after immunization with a multiclade envelope HIV vaccine candidate. Vaccine 2005;23:3434-3445.
11. D'Costa S, Slobod KS, Webster RG, White SW, and Hurwitz JL: Structural features of HIV envelope defined by antibody escape mutant analysis. AIDS Res Hum Retroviruses 2001;17(12): 1205-1209.
12. Barouch DH, Kunstman J, Glowczwskie J, et al.: Viral escape from dominant simian immunodeficiency virus epitope-specific cytotoxic T lymphocytes in DNA-vaccinated rhesus monkeys. J Virol 2003;77(13):7367-7375.
13. Sjolander S, Bolmstedt A, Akerblom L, et al.: N-linked glycans in the CD4-binding domain of human immunodeficiency virus type 1 envelope glycoprotein gp160 are essential for the in vivo priming of T cells recognizing an epitope located in their vicinity. Virology 1996;215(2):124-133.
14. Hurwitz JL, Slobod KS, Lockey TD, et al.: Application of the polyvalent approach to HIV-1 vaccine development. Curr Drug Targets Infect Disord 2005;5(2):143-156.
15. Stambas J, Brown SA, Gutierrez A, et al.: Long lived multi-isotype anti-HIV antibody responses following a prime-double boost immunization strategy. Vaccine 2005;23(19):2454-2464.